Roth Capital Starts Sophiris Bio (SPHS) at Buy, $8 PT

September 15, 2016 7:14 AM EDT
Get Alerts SPHS Hot Sheet
Price: $3.23 +11.38%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade SPHS Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Roth Capital initiates coverage on Sophiris Bio (NASDAQ: SPHS) with a Buy rating and a price target of $8.00.

Analyst Joseph Pantginis commented, "We are initiating coverage of Sophiris with a Buy rating and $8 price target. The company's lead asset, PRX302 has the potential to address the large markets of benign prostate hyperplasia (BPH) with a positive Phase III in hand and localized prostate cancer."

He added, "We see both BPH and PCa as indications with significant unmet clinical needs, and view PRX302 as a complement to current surgical and non-surgical approaches. With a product now in late-stage clinical development and positive data in hand, we urge investors to consider the investment case ahead of upcoming catalysts."

For an analyst ratings summary and ratings history on Sophiris Bio click here. For more ratings news on Sophiris Bio click here.

Shares of Sophiris Bio closed at $2.85 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Roth Capital

Add Your Comment